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Background: In human medicine, adverse outcomes associated with switching between bioequivalent brand name
and generic antiepileptic drug products is a subject of concern among clinicians. In veterinary medicine, epilepsy in
dogs is usually treated with phenobarbital, either with the standard brand name formulation Luminal® or the veterinary
products Luminal® vet and the generic formulation Phenoleptil®. Luminal® and Luminal® vet are identical 100 mg tablet
formulations, while Phenoleptil® is available in the form of 12.5 and 50 mg tablets. Following approval of Phenoleptil®
for treatment of canine epilepsy, it was repeatedly reported by clinicians and dog owners that switching from Luminal®
(human tablets) to Phenoleptil® in epileptic dogs, which were controlled by treatment with Luminal®, induced
recurrence of seizures. In the present study, we compared bioavailability of phenobarbital after single dose
administration of Luminal® vet vs. Phenoleptil® with a crossover design in 8 healthy Beagle dogs. Both drugs were
administered at a dose of 100 mg/dog, resulting in 8 mg/kg phenobarbital on average.
Results: Peak plasma concentrations (Cmax) following Luminal® vet vs. Phenoleptil® were about the same in most dogs
(10.9 ± 0.92 vs. 10.5 ± 0.77 μg/ml), and only one dog showed noticeable lower concentrations after Phenoleptil® vs.
Luminal® vet. Elimination half-life was about 50 h (50.3 ± 3.1 vs. 52.9 ± 2.8 h) without differences between the
formulations. The relative bioavailability of the two products (Phenoleptil® vs. Luminal® vet.) was 0.98 ± 0.031, indicating
that both formulations resulted in about the same bioavailability.
Conclusions: Overall, the two formulations did not differ significantly with respect to pharmacokinetic parameters
when mean group parameters were compared. Thus, the reasons for the anecdotal reports, if true, that switching from
the brand to the generic formulation of phenobarbital may lead to recurrence of seizures are obviously not related to a
generally lower bioavailability of the generic formulation, although single dogs may exhibit lower plasma levels after
the generic formulation that could be clinically meaningful.
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Epilepsy is a frequently occurring neurological brain disease
in dogs [1-3]. Epilepsy in dogs can be difficult to medically
control in some cases, which can lead to premature death
[4]. The most common and first-choice therapy of canine
epilepsy is daily oral administration of the antiepileptic drug
phenobarbital, which symptomatically suppresses seizures
[5-7]. Phenobarbital was introduced as a hypnotic and
antiepileptic drug under the brand name Luminal® 100 years
ago [8]. In order to obtain seizure control, it is recommended
that plasma concentrations of phenobarbital be maintained
within a therapeutic range of 10-40 μg/ml [9]. Two oral
formulations of phenobarbital are approved for treatment of
canine epilepsy in Europe, Phenoleptil® and Luminal® vet.
Phenoleptil® is available in the form of 12.5 and 50 mg tab-
lets, while Luminal® vet is available in the form of 100 mg
tablets and, under the name Luminaletten® vet, as 15 mg tab-
lets. Luminal® is also the trade name of the human 100 mg
tablets of phenobarbital and both products (Luminal® and
Luminal® vet) are produced by the same pharmaceutical
company. Before Phenoleptil® and, later, Luminal® vet were
approved for treatment of canine epilepsy, epileptic dogs
were commonly treated with human Luminal® tablets.
Following approval of Phenoleptil® for treatment of canine
epilepsy, many dogs that were previously treated with human
Luminal® tablets were switched to Phenoleptil®. However, it
was repeatedly reported by clinicians and dog owners that
switching from Luminal® (human tablets) to Phenoleptil® in
epileptic dogs, which were controlled by treatment with
Luminal®, induced recurrence of seizures. In humans with
epilepsy, multiple studies and case reports have described
relapses and worsening clinical outcome after a switch from
a brand name to a generic medication [10-13]. The most
likely explanation for this observation in dogs would be a
lower bioavailability of phenobarbital from Phenoleptil® vs.
Luminal®. To our knowledge, no bioequivalence studies on
Phenoleptil® vs. Luminal® are available in dogs. Two pharma-
cokinetic measures, the area-under-the-curve (AUC) of the
drug concentration-time curve and the maximum plasma
concentration (Cmax) are used to determine bioequivalence
of a generic formulation to the brand product [14]. Because
the tablet formulation of Luminal® vet is identical with the
standard brand name formulation Luminal®, we directly
compared these pharmacokinetic measures of pheno-
barbital after single dose administration of Luminal®
vet vs. Phenoleptil® with a crossover design in healthy Bea-
gle dogs. Our hypothesis was that Cmax and bioavailability
of phenobarbital differ between the two pharmaceutical
formulations, at least in individual dogs.
Methods
Animals and study design
Eight healthy Beagle dogs (2 females, 3 castrated fe-
males, and 3 castrated males) were used. They ranged inage from 1-4 years and their body weight ranged from 9.0-
17.2 kg (mean 12.7 kg) at the time of the experiments. The
study was designed as an open, randomized single-dose
cross-over study. Experiments were performed according
to the EU council directive 86/609/EWG and the German
Law on Animal Protection (“Tierschutzgesetz”). Ethical
approval for the study was granted by an ethical committee
(according to §15 of the Tierschutzgesetz) and the govern-
ment agency (Lower Saxony State Office for Consumer
Protection and Food Safety; LAVES) responsible for
approval of animal experiments in Lower Saxony (reference
number for this project: 11A158). All efforts were made to
minimize suffering of the dogs.
Medication
Using a cross-over design, all dogs were treated with
100 mg tablets Luminal® vet (Desitin Arzneimittel;
Hamburg, Germany) or 50 mg tablets Phenoleptil®
(CP-Pharma, Burgdorf, Germany). Tablets were orally
administered at a single dose of 100 mg phenobarbital per
dog, i.e. two undivided 50 mg tablets of Phenoleptil® or
one undivided 100 mg tablet of Luminal® vet per dog.
Based on body weight of the individual dogs, this resulted
in doses of 5.8-11.1 mg/kg (mean 7.95 mg/kg) for both
formulations of phenobarbital.
Both pharmaceutical formulations were administered in
an open, randomized single-dose cross-over design, i.e. four
dogs were orally treated with Luminal® vet first and after a
wash-out period of three weeks with Phenoleptil®. The
other four dogs were treated reciprocally. Administration of
tablets was performed about 24 hours after the last feeding.
The dogs were fed again one hour following drug adminis-
tration. The dogs had free access to water during the study.
Blood sampling
Before and 0.5, 1, 2, 4, 6, 8, 10, 23, 32, 47, 56, 71, 80, 95,
104, and 119 hours following drug administration,
venous blood samples of about 1 ml were taken. For
the first eight samples, an indwelling catheter was implanted
into the vena cephalica antebrachii. Subsequent samples
were taken via single puncture of the vena cephalica
antebrachii or vena saphena. Blood was collected in tubes
preloaded with 20 μl 5 mM EDTA, stored on ice for
a maximum of 1 hour, and centrifuged. Plasma was
stored at -20°C until analysis by high performance liquid
chromatography (HPLC).
HPLC analysis
Phenobarbital concentrations in plasma samples were de-
termined by HPLC with UV detection as described previ-
ously [15]. In short, 50 μl of plasma were mixed with 150 μl
methanol, centrifuged and the supernatant injected into the
HPLC apparatus equipped with a pre-column (Nucleosil
120–5 C18, 60 × 4 mm; Knauer, Berlin, Germany), a main
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Figure 1 (See legend on next page.)
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Figure 1 Comparison of individual plasma concentration time curves of phenobarbital following oral administration of two different
phenobarbital formulations. Individual plasma levels after administration of Luminal® vet are shown as solid symbols and lines and those of
Phenoleptil® as open symbols and hyphenated lines in 8 dogs. Each of the 8 dogs received both formulations with an interval of three weeks
between the two experiments. The dose of phenobarbital was 100 mg per dog, resulting in the mg/kg doses indicated in the graphs.
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Macherey and Nagel, Düren, Germany), and an UV
detector (SPD- 6A; Shimadzu, Duisburg, Germany). The
mobile phase was composed of 0.05 M phosphate buffer
and acetonitrile in a volume ratio of 68 to 32 (pH adjusted
to 5.6). The flow rate of the mobile phase was 1 ml/min.
Retention time of phenobarbital under these conditions
amounted to ~6.8 min. As control, reference samples of
known phenobarbital concentration were quantified every
day. Limit of detection for phenobarbital was 0.2 μg/ml
and limit of quantification was 0.4 μg/ml.Calculation of results and statistics
For statistical calculation and illustration of results,
GraphPad Prism 5 (La Jolla, CA, USA) was used.
Time-dependent changes in plasma concentration
were modeled individually, using WinNonlin (Pharsight,
St. Louis, Missouri, USA). Pharmacokinetic parameters
(Cmax, peak plasma concentration; tmax, time until Cmax is
reached; t0.5, elimination half-life; AUC, area under plasma
concentration curves) were calculated using a single-
compartment model. The relative bioavailability was
calculated by dividing AUC for Phenoleptil® by the AUC






































Figure 2 Comparison of mean plasma concentration time curves of p
phenobarbital formulations. Mean plasma levels after administration of L
Phenoleptil® as open symbols and hyphenated lines. Data are shown as mas mean ± standard error of the mean (SEM). Group differ-
ences were calculated by paired Student’s t-test (p < 0.05).Results
Individual data of phenobarbital plasma concentrations
following the two formulations are shown in Figure 1,
group means in Figure 2. Apart from an apparently
slightly faster initial phenobarbital accumulation in
blood following Phenoleptil® administration in 4 of the 8
dogs, plasma concentration curves of the two tested
formulations were very similar (Figure 1). Only in dog #3,
peak plasma levels of phenobarbital were clearly higher
after administration of Luminal® vet. vs. Phenoleptil®
(Figure 1). The variation in plasma levels from dog to dog
was mainly a function of the different doses (in mg/kg)
resulting from the fact that all dogs received the same
overall dose (100 mg) but differed in body weight. When
the observed maximal plasma concentration (Cmax;
ranging from 7.95 to 15.3 μg/ml) was plotted against
dose in mg/kg, a linear relationship was obtained for
both formulations of phenobarbital (Figure 3).
When pharmacokinetic parameters were calculated
from the plasma concentration vs. time curves shown in
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Figure 3 Correlation between individual phenobarbital doses
and maximal plasma concentrations. As a result of the different
body weights of the 8 dogs, doses of phenobarbital ranged
between 5.8 and 11.1 mg/kg, resulting in different peak plasma
levels (Cmax). As shown in the graph, a linear correlation between
Cmax and dose was obtained for both phenobarbital formulations
without difference between formulations.
Bankstahl et al. BMC Veterinary Research 2013, 9:202 Page 5 of 7
http://www.biomedcentral.com/1746-6148/9/202between the two phenobarbital formulations. As shown
in Table 1, the mean time to reach peak plasma concen-
trations (Tmax) tended to be higher after Luminal® vet vs.
Phenoleptil® (P = 0.0588 for the calculated Tmax), but,
again, no statistical significance was obtained between
the two formulations. Mean peak concentration (Cmax)
values in plasma were about 10 μg/ml without difference
between formulations. The mean elimination half-life
(t0.5) in plasma was about 50 h (range 37-63 h). When
the relative bioavailability was calculated by dividing
AUC for Phenoleptil® by the AUC of Luminal® vet, aTable 1 Pharmacokinetic parameters of phenobarbital follow







AUC(0-119) (μg ml-1 h) observed
AUC∞ (μg ml-1 h) calculated
Relative bioavailability (AUCPhenoleptil® /AUCLuminal® vet)
Relative Cmax observed (Cmax, observed Phenoleptil®/ Cmax, observed Luminal® vet)
Relative Cmax calculated (Cmax, calculated, Phenoleptil®)/Cmax, calculated, Luminal® vet)
All data are shown as means ± SEM; for ratios also the range and 90% confidence in
concentration; Cmax, peak plasma concentration; t0.5, elimination half-life in plasma;mean value of 0.98 (range 0.90-1.15) was obtained, indi-
cating that both formulations resulted in about the same
bioavailability (Table 1). Even dog #3, which exhibited
the most marked difference in peak plasma concentra-
tions between the two formulations (Figure 1), resulting
in a relative bioavailability of 0.92, stayed within the
80-125% criterion of bioequivalence [11].
Discussion
The present study had two major aims. First, to
determine the pharmacokinetics of phenobarbital follow-
ing oral administration of the newly licensed veterinary
product Luminal® vet in dogs. The second aim of this
study was to compare the bioavailability of the pharma-
ceutical formulations “Luminal® vet 100 mg“ (Desitin) and
“Phenoleptil® 50 mg“ (CP-Pharma) following a single oral
dose in dogs.
Following administration of 100 mg tablets Luminal®
vet (one tablet per dog), phenobarbital was rapidly
absorbed and peak plasma levels of 8-15 μg/ml were
reached within 2-4 h in most dogs. Elimination was slow
with half-lives ranging from 37-63 h. The data obtained
from pharmacokinetic analysis of plasma concentration
time curves of phenobarbital were comparable to those
previously reported for Luminal® in dogs [16,17]. In the
study of Al-Tahan and Frey [17], Luminal® tablets were
used at a dose of 10 mg/kg, resulting in a bioavailability
of 86-96% compared to i.v. administration of the same dose.
Elimination half-life was 52 h after oral administration,
which is almost identical with the mean half-live of 50 h
determined for Luminal® vet in the present study.
A second reason to perform this study was anecdotal
evidence (repeatedly reported by clinicians) that switchinging oral administration of 100 mg Luminal® vet or
Luminal® vet Phenoleptil® P
3.75 ± 0.79 2.75 ± 0.37 0.2275
5.97 ± 1.33 2.64 ± 0.51 0.0588
10.9 ± 0.92 10.5 ± 0.77 0.2426
10.3 ± 0.92 10.0 ± 0.85 0.2569
50.3 ± 3.1 52.9 ± 2.8 0.2348
644 ± 52.5 618 ± 44.5 0.1499
807 ± 66.8 781 ± 54.0 0.2961
0.98 ± 0.031
(range: 0.90-1.15; 90% CI: 0.92-1.04)
0.96 ± 0.031
(range: 0.85-1.05; 90% CI: 0.90-1.03)
0.97 ± 0.028
(range: 0.81-1.08; 90% CI: 0.92-1.03)
tervals (90% CI) are shown. Abbreviations: Tmax, time to reach peak plasma
AUC, area under the plasma concentration curve.
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dogs, which were controlled by treatment with Luminal®,
induced recurrence of seizures. The most likely explanation
for this observation would be a lower bioavailability of
phenobarbital from Phenoleptil® vs. Luminal®. Because the
tablet formulation of Luminal® vet is identical with
the formulation used in Luminal®, we directly compared
bioavailability of phenobarbital after single dose administra-
tion of Luminal® vet vs. Phenoleptil® with a crossover design
in healthy Beagle dogs. In contrast to our expectations,
both formulations had the same relative bioavailability.
Only one (#3) of the 8 dogs used for the present study
showed clearly higher peak plasma levels of phenobarbital
after Luminal® vet vs. Phenoleptil®. Peak plasma levels were
reached more rapidly with Phenoleptil® in several dogs,
which is most likely a consequence of the fact that the latter
formulation was administered as two tablets of 50 mg,
which may be dissolved faster in the gastrointestinal tract
than the one 100 mg tablet of Luminal® vet. However, in
our opinion, the resulting difference in Tmax was too small
to be of any clinical relevance.
Beagles, which were used for the present study, were
previously shown to eliminate phenobarbital more than 2
times more rapidly than Mongrels [16]. Such differences
in the elimination rate of phenobarbital in different breeds
of dogs have to be considered when treating dogs with this
drug. However, we do not believe that such strain differ-
ences can explain the apparent discrepancy between the
study results and the anecdotal clinical finding of poor
seizure control after switching formulations.
In humans with epilepsy, loss of response after switching
from brand name to bioequivalent generic formulations is
a well-known phenomenon [10-12,14,18,19]. The use of
pharmacokinetic bioequivalence as an indicator of thera-
peutic and clinical equivalence, the lack of appropriate
studies comparing generic and brand name medications
and differences in excipients are some of the factors that
could explain variation in clinical response between generic
and brand name medications [14,18,19]. Indeed, subtle
differences in pharmacokinetic parameters between two
formulations can produce clinically important differences
in seizure control [14]. Furthermore, in case of phenobar-
bital, one additional reason may result from the fact that
tolerance and physical dependence develops during chronic
administration of this drug [20,21], so that withdrawal sei-
zures may occur during switching from one formulation to
another if a too marked decline of phenobarbital levels is
not avoided during switching. In view of the consequences
of increased seizure activity resulting from subtherapeutic
serum drug concentration, the American Academy of
Neurology (AAN) issued a position statement in 2007
opposing generic antiepileptic drug substitution without
physician approval [22]. Although the present study with
single doses of phenobarbital in healthy Beagle dogs did notindicate that switching from the standard brand name
formulation to generic phenobarbital results in lower
bioavailability in most dogs, moderate differences in
peak concentrations between formulations occurred.
Subsequent studies should evaluate whether prolonged
administration of these formulations results in more marked,
clinically meaningful differences.
Conclusions
In summary, the present study with Luminal® vet con-
firmed the favorable pharmacokinetics of phenobarbital
for treatment of epilepsy in dogs. The rapid absorption
and long half-life are important advantages for mainten-
ance treatment of epilepsy in this species. With respect
to the anecdotal reports that seizures may occasionally
recur when switching treatment from Luminal® to
Phenoleptil® in epileptic dogs, only one (#3) of the 8
dogs showed clear deviations between the two dosage
forms in peak concentration and AUC , which may be
an indication of a clinically important between-dosage
form variability. However, on average both phenobarbital
formulations produced almost the same plasma levels in
dogs and had an almost identical relative bioavailability.
Thus, the reasons for the anecdotal findings, if true,
need to be further explored.
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